Monogram announces availability of HERmark and HER1 and HER3 Total Protein
Assays in Collaborative Biomarker Study
SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators have presented additional clinical results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 total protein and homodimer levels and predict response to Herceptin(R) (trastuzumab) in patients with metastatic breast cancer at the 44th ASCO Annual Meeting taking place in Chicago, Illinois. Monogram also announced the initiation of a Collaborative Biomarker Study involving the company's HERmark Breast Cancer Assay and the HER1 and HER3 Total Protein Assays.
"HERmark is the first diagnostic built upon our VeraTag technology," said Monogram CEO Bill Young. "Today we are announcing two developments that will elevate the profile of HERmark in the oncology community. First, important clinical data presented today demonstrates the superiority of HERmark over FISH testing for HER2. Second, we are initiating a study that will provide an opportunity for participating oncologists to experience first hand the superiority of HERmark in their clinical practices. We look forward to completing our commercial planning and to a future commercial launch of HERmark throughout the U.S."
HERmark Clinical Data
The oral presentation, entitled "Total HER2 and HER2 Homodimer Levels
Predict Response to trastuzumab," discussed the findings of a study that
investigated the HERmark assay's ability to identify and discriminate among
patients with metastatic breast cancer who experienced different degrees of
response to trastuzumab. The stu
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved